Italy stocks lower at close of trade; Investing.com Italy 40 down 0.02%

Investing.com – Germany stocks were mixed after the close on Monday, as gains in the Food & Beverages, Industrials and Pharmaceuticals & Healthcare sectors led shares higher while losses in the Construction, Consumer & Cyclical and Retail sectors led shares lower.

At the close in Frankfurt, the DAX gained 0.11%, while the MDAX index fell 0.08%, and the TecDAX index lost 0.66%.

The best performers of the session on the DAX were Bayer AG NA (ETR:BAYGN), which rose 4.70% or 1.57 points to trade at 34.87 at the close. Meanwhile, Rheinmetall AG (ETR:RHMG) added 3.63% or 55.50 points to end at 1,585.00 and Deutsche Bank AG NA O.N. (ETR:DBKGn) was up 1.35% or 0.42 points to 31.53 in late trade.

The worst performers of the session were GEA Group AG (ETR:G1AG), which fell 5.02% or 2.90 points to trade at 54.85 at the close. Vonovia SE (ETR:VNAn) declined 4.87% or 1.24 points to end at 24.21 and Symrise AG Inh. O.N. (ETR:SY1G) was down 3.50% or 2.42 points to 66.82.

The top performers on the MDAX were flatexDEGIRO AG (ETR:FTKn) which rose 5.67% to 33.54, RENK Group AG (ETR:R3NK) which was up 5.53% to settle at 54.57 and Bilfinger SE O.N. (ETR:GBFG) which gained 4.08% to close at 104.50.

The worst performers were Tag Immobilien AG (ETR:TEGG) which was down 5.74% to 13.14 in late trade, Puma SE (ETR:PUMG) which lost 4.88% to settle at 20.06 and Gerresheimer AG (ETR:GXIG) which was down 4.10% to 24.80 at the close.

The top performers on the TecDAX were Hensoldt Ag (ETR:HAGG) which rose 2.19% to 69.95, Evotec AG O.N. (ETR:EVTG) which was up 1.36% to settle at 5.50 and Elmos Semiconductor AG (ETR:ELGG) which gained 0.59% to close at 102.00.

The worst performers were PNE Wind AG (ETR:PNEGn) which was down 3.33% to 9.86 in late trade, Aixtron SE (ETR:AIXGn) which lost 3.33% to settle at 17.74 and Siltronic AG (ETR:WAFGn) which was down 2.76% to 47.90 at the close.

Falling stocks outnumbered advancing ones on the Frankfurt Stock Exchange by 377 to 266 and 24 ended unchanged.

Shares in Bayer AG NA (ETR:BAYGN) rose to 52-week highs; up 4.70% or 1.57 to 34.87. Shares in Symrise AG Inh. O.N. (ETR:SY1G) fell to 5-year lows; falling 3.50% or 2.42 to 66.82. Shares in Bilfinger SE O.N. (ETR:GBFG) rose to all time highs; rising 4.08% or 4.10 to 104.50. Shares in Elmos Semiconductor AG (ETR:ELGG) rose to all time highs; gaining 0.59% or 0.60 to 102.00.

The DAX volatility index, which measures the implied volatility of DAX options, was down 2.26% to 15.94 a new 1-month low.

Gold Futures for February delivery was down 0.60% or 25.55 to $4,217.45 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January fell 1.58% or 0.95 to hit $59.13 a barrel, while the February Brent oil contract fell 1.52% or 0.97 to trade at $62.78 a barrel.

EUR/USD was unchanged 0.19% to 1.16, while EUR/GBP unchanged 0.05% to 0.87.

The US Dollar Index Futures was up 0.21% at 99.17.

Investing.com – France stocks were lower after the close on Monday, as losses in the Consumer Goods, Consumer Services and Technology sectors led shares lower.

At the close in Paris, the CAC 40 lost 0.08%, while the SBF 120 index fell 0.07%.

The best performers of the session on the CAC 40 were Societe Generale SA (EPA:SOGN), which rose 1.76% or 1.08 points to trade at 62.62 at the close. Meanwhile, Unibail-Rodamco-Westfield SE (EPA:URW) added 1.70% or 1.52 points to end at 90.74 and Legrand SA (EPA:LEGD) was up 1.59% or 2.05 points to 130.80 in late trade.

The worst performers of the session were Edenred SA (EPA:EDEN), which fell 5.65% or 1.07 points to trade at 17.86 at the close. Teleperformance SE (EPA:TEPRF) declined 3.19% or 1.92 points to end at 58.18 and Compagnie de Saint Gobain SA (EPA:SGOB) was down 2.26% or 1.96 points to 84.78.

The top performers on the SBF 120 were Emeis SA (EPA:EMEIS) which rose 6.93% to 14.20, Forvia (EPA:FRVIA) which was up 3.10% to settle at 13.31 and Fnac Darty SA (EPA:FNAC) which gained 2.99% to close at 29.25.

The worst performers were Edenred SA (EPA:EDEN) which was down 5.65% to 17.86 in late trade, SES (EPA:SESFd) which lost 3.99% to settle at 5.30 and Ubisoft Entertainment (EPA:UBIP) which was down 3.55% to 6.09 at the close.

Falling stocks outnumbered advancing ones on the Paris Stock Exchange by 260 to 227 and 92 ended unchanged.

Shares in Societe Generale SA (EPA:SOGN) rose to 5-year highs; up 1.76% or 1.08 to 62.62. Shares in Edenred SA (EPA:EDEN) fell to 5-year lows; falling 5.65% or 1.07 to 17.86. Shares in Edenred SA (EPA:EDEN) fell to 5-year lows; falling 5.65% or 1.07 to 17.86. Shares in Forvia (EPA:FRVIA) rose to 52-week highs; rising 3.10% or 0.40 to 13.31.

The CAC 40 VIX, which measures the implied volatility of CAC 40 options, was unchanged 0.00% to 18.96 a new 52-week high.

Gold Futures for February delivery was down 0.61% or 25.80 to $4,217.20 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January fell 1.55% or 0.93 to hit $59.15 a barrel, while the February Brent oil contract fell 1.49% or 0.95 to trade at $62.80 a barrel.

EUR/USD was unchanged 0.18% to 1.16, while EUR/GBP unchanged 0.06% to 0.87.

The US Dollar Index Futures was up 0.20% at 99.17.

Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock surged 14.7% Monday after the company announced it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-MAPT, its investigational RNAi therapeutic targeting tauopathies including Alzheimer’s disease.

The trial marks a significant milestone for Arrowhead’s CNS delivery technology, as ARO-MAPT utilizes a new proprietary delivery system designed to cross the blood-brain barrier after subcutaneous injection. In preclinical studies, the therapy demonstrated potent suppression of tau protein throughout the central nervous system.

ARO-MAPT aims to silence the gene that encodes tau protein, potentially preventing or reversing tau accumulation in early Alzheimer’s disease patients. The approach targets tau-related pathology, which is considered a critical driver of neurodegeneration, rather than focusing on amyloid-beta plaque clearance like currently available treatments.

"By silencing expression of the gene that encodes the tau protein, ARO-MAPT may prevent or reverse tau protein accumulation in subjects with early Alzheimer’s disease, potentially preventing or slowing the progression of the disease," said James Hamilton, Chief Medical Officer and Head of R&D at Arrowhead.

The ongoing study will evaluate single and multiple doses in both healthy volunteers and patients with early Alzheimer’s disease. Initial data from the first parts of the study is expected in the second half of 2026.

Preclinical studies in non-human primates showed long-lasting suppression of tau protein, suggesting the potential for monthly or quarterly subcutaneous dosing with uniform distribution throughout the CNS.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Netflix’s acquisition of Warner Bros. and HBO could mark a turning point for the streaming giant, one that Morgan Stanley says carries “clear risks” but, if executed well, could deepen its competitive moat for years.

Analyst Benjamin Swinburne writes that Netflix is effectively betting that “the combination of WB’s content and Netflix’s distribution can create value above and beyond the purchase price.” 

The deal, valued at more than $80 billion, assigns the assets roughly 25x EV/EBITDA, or ~14x on a fully synergized basis once $2–3 billion in cost synergies are included.

Morgan Stanley says near-term financials look workable, with WB and HBO’s adjusted EBITDA growth plus synergies “suggesting GAAP EPS accretion in year two of acquisition.” 

But the real test will be whether Netflix can migrate Warner Bros.’ and HBO’s vast libraries into global streaming hits, according to Swinburne.

Netflix has previously taken external IP and turned it into cultural moments. “We have seen clear examples of Netflix taking IP off one platform (Breaking Bad/AMC Network, Cobra Kai/YouTube, Suits/USA) and creating massive hits on its own service,” the analyst wrote. 

Morgan Stanley argues the acquisition would allow Netflix to “tap into WB’s IP… but at even greater scale.”

HBO, meanwhile, brings a brand “synonymous with prestige TV” and a library that should bolster both engagement and pricing power.

Morgan Stanley maintains an Overweight rating on Netflix, calling the risk/reward “compelling.”